Real-Time Cap Table Data
Now in Neuron Through
Shareworks API
Real-Time Cap Table Data
Now in Neuron Through
Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.
For six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Firm Advises NanoCellect on IP Matters Related to $35 Million Series C & D Financing
On September 16, 2021, microfluidic cell sorting company NanoCellect Biomedical announced the closing of $35 million in Series C and D financing rounds. The $15 million Series C round was led by Vertical Venture Partners (VVP) and joined by existing investors Agilent, Illumina Ventures, and FusionX Ventures, as well as new investors Yonjin Capital and Sagian Equity. The $20 million Series D round was led by Warburg Pincus, with participation from new investor Casdin Capital, joined by existing investors Illumina Ventures, VVP, Anzu Partners, FusionX Ventures, and Sagian Equity. Wilson Sonsini Goodrich & Rosati advises NanoCellect on IP matters and represented the company in patent matters related to the Series C and D financing rounds.
Client Highlights
Wilson Sonsini Advises Transcarent on Partnership with Walmart
On October 15, 2021, Walmart and Transcarent announced that they will be working together as go-to-market partners for self-insured employers across the country. Their agreement allows Transcarent, which offers employers and their dependents a new, different, and better health and care experience, to share Walmart’s everyday low cost on pharmaceuticals and other services with self-insured employers and their employees for the first time. Wilson Sonsini Goodrich & Rosati advised Transcarent on the transaction.
The collaboration makes it easier for millions of employees and the families of self-insured employers to access high-value care—no matter where they live—at affordable prices. This new offering will allow employers of all sizes to leverage Walmart’s health care size and scale to more easily provide their employees convenient care and cost-effective health and wellness options.
“Together, Walmart and Transcarent have the scale and innovation required to transform the way health and care are delivered and paid for across the nation, regardless of a person’s economic or geographic situation,” said Glen Tullman, chief executive officer of Transcarent. “Transcarent is putting employers and employees back in charge of their health and care. Employees can trust that Transcarent will focus on value and quality first, provide clear and unbiased information, offer a full range of choices, and share the rewards with employees that their better health decisions generate.”
The Wilson Sonsini team that advised Transcarent on the transaction includes technology transactions partner Chris Paniewski and Of Counsel Scott McKinney and corporate partner Mark Baudler and associate Jonathan Chan.
For more information, please see the companies’ joint press release.
The collaboration makes it easier for millions of employees and the families of self-insured employers to access high-value care—no matter where they live—at affordable prices. This new offering will allow employers of all sizes to leverage Walmart’s health care size and scale to more easily provide their employees convenient care and cost-effective health and wellness options.
“Together, Walmart and Transcarent have the scale and innovation required to transform the way health and care are delivered and paid for across the nation, regardless of a person’s economic or geographic situation,” said Glen Tullman, chief executive officer of Transcarent. “Transcarent is putting employers and employees back in charge of their health and care. Employees can trust that Transcarent will focus on value and quality first, provide clear and unbiased information, offer a full range of choices, and share the rewards with employees that their better health decisions generate.”
The Wilson Sonsini team that advised Transcarent on the transaction includes technology transactions partner Chris Paniewski and Of Counsel Scott McKinney and corporate partner Mark Baudler and associate Jonathan Chan.
For more information, please see the companies’ joint press release.
Client Highlights
Wilson Sonsini Represents FREYR in Joint Venture with Koch Strategic Platforms to Advance Clean Energy in U.S.
On October 12, 2021, FREYR Battery, a developer of clean, next-generation battery cell production capacity, announced the formation of a joint venture in the United States between Koch Strategic Platforms (KSP) and FREYR. The joint venture, which has a 50/50 percent ownership structure, has been established to develop an initial 50 GWh of Gigafactory-scale battery cell manufacturing capacity in the U.S. based on 24M Technologies SemiSolidTM platform technology. The scale and scope of the targeted development would position the joint venture as one of the largest battery cell manufacturers in the U.S., using American-borne technology and the sustainable innovation of a premier U.S.-based, global industrial partner in KSP. This venture further progresses FREYR’s strategic focus of developing clean, localized battery cell production and supply chains to catalyze emerging energy technology adoption.
Client Highlights
Wilson Sonsini Represents Track 1099 in Its Acquisition by Avalara
On October 1, 2021, Avalara, a leading provider of tax compliance automation software for businesses of all sizes, announced it has acquired Track1099 LLC, a company that provides online software and services for cost-effectively managing, e-filing, and e-delivering IRS forms, including 1099s, W-2s, W-9s, and more. Wilson Sonsini Goodrich & Rosati represented Track1099 in the transaction.
Client Highlights
Wilson Sonsini Advises ALX Oncology on Acquisition of ScalmiBio
On October 7, 2021, ALX Oncology Holdings Inc. (ALX Oncology), a clinical-stage immuno-oncology company, and ScalmiBio, Inc., announced that ALX has acquired ScalmiBio. Wilson Sonsini Goodrich & Rosati represented ALX Oncology in the transaction.
Client Highlights
Wilson Sonsini Advises Twitter on $1.05 Billion Sale of MoPub to AppLovin
On October 6, 2021, Twitter, Inc. announced that it has entered into a definitive agreement to sell MoPub to AppLovin Corporation, a leading marketing software company, for $1.05 billion in cash. The transaction will enable Twitter to accelerate the development of owned and operated revenue products and drive growth across key areas for the service, including performance-based advertising, small and medium-sized business (SMB) offerings, and commerce initiatives. Twitter believes AppLovin is well positioned to grow and evolve MoPub’s network of customers in the rapidly changing in-app industry. Wilson Sonsini Goodrich & Rosati is advising Twitter on the transaction.
According to Twitter CEO Jack Dorsey, “This transaction increases our focus and demonstrates confidence in our revenue product roadmap, accelerating our ability to invest in the core products that position Twitter for long-term growth and best serve the public conversation. We thank the incredible teams and customers who have contributed to making MoPub a success within Twitter over the years.”
According to Twitter CEO Jack Dorsey, “This transaction increases our focus and demonstrates confidence in our revenue product roadmap, accelerating our ability to invest in the core products that position Twitter for long-term growth and best serve the public conversation. We thank the incredible teams and customers who have contributed to making MoPub a success within Twitter over the years.”
2021 Mid-Year Technology and Life Sciences IPO Report
We are pleased to present the 2021 Mid-Year Technology and Life Sciences IPO Report, which provides analyses related to the pricing of 123 initial public offerings completed by U.S.-based technology and life sciences companies between January 1 and June 30, 2021. The report includes IPO filing, pricing, and value statistics; governance details; ownership and structure factors; and defensive measure data points. It also briefly discusses concurrent private placements, indications of interest, direct listings, and SPACs.